RU2008146518A - Биомаркеры инфекции, вызываемой вирусом гепатита с - Google Patents

Биомаркеры инфекции, вызываемой вирусом гепатита с Download PDF

Info

Publication number
RU2008146518A
RU2008146518A RU2008146518/13A RU2008146518A RU2008146518A RU 2008146518 A RU2008146518 A RU 2008146518A RU 2008146518/13 A RU2008146518/13 A RU 2008146518/13A RU 2008146518 A RU2008146518 A RU 2008146518A RU 2008146518 A RU2008146518 A RU 2008146518A
Authority
RU
Russia
Prior art keywords
genes
individual
expression
infection
characteristic set
Prior art date
Application number
RU2008146518/13A
Other languages
English (en)
Russian (ru)
Inventor
Рави К. РАМАЧАНДРАН (US)
Рави К. РАМАЧАНДРАН
Мэттью В. ХАРДИНГ (US)
Мэттью В. ХАРДИНГ
Пол Р. КАРОН (US)
Пол Р. КАРОН
Мартин К. БОТФИЛД (US)
Мартин К. БОТФИЛД
Брайан Дж. ХЭР (US)
Брайан Дж. ХЭР
Радж БАНДАРУ (US)
Радж БАНДАРУ
Кевин М. КЕЛЛИХЕР (US)
Кевин М. КЕЛЛИХЕР
Катрин Н. КОРНЕЛЛ (US)
Катрин Н. КОРНЕЛЛ
Original Assignee
Вертекс Фармасьютикалз Инкорпорейтед (Us)
Вертекс Фармасьютикалз Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вертекс Фармасьютикалз Инкорпорейтед (Us), Вертекс Фармасьютикалз Инкорпорейтед filed Critical Вертекс Фармасьютикалз Инкорпорейтед (Us)
Publication of RU2008146518A publication Critical patent/RU2008146518A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2008146518/13A 2006-04-26 2007-04-25 Биомаркеры инфекции, вызываемой вирусом гепатита с RU2008146518A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79552006P 2006-04-26 2006-04-26
US60/795,520 2006-04-26

Publications (1)

Publication Number Publication Date
RU2008146518A true RU2008146518A (ru) 2010-06-10

Family

ID=38656353

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008146518/13A RU2008146518A (ru) 2006-04-26 2007-04-25 Биомаркеры инфекции, вызываемой вирусом гепатита с

Country Status (13)

Country Link
US (1) US20100028874A1 (enExample)
EP (1) EP2016195A4 (enExample)
JP (1) JP2009535036A (enExample)
KR (1) KR20090023360A (enExample)
CN (1) CN101479389A (enExample)
AU (1) AU2007244824A1 (enExample)
CA (1) CA2650616A1 (enExample)
IL (1) IL194920A0 (enExample)
MX (1) MX2008013796A (enExample)
NO (1) NO20084954L (enExample)
NZ (1) NZ573052A (enExample)
RU (1) RU2008146518A (enExample)
WO (1) WO2007127801A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
JP2009178057A (ja) * 2008-01-29 2009-08-13 Miyazakiken Sangyo Shien Zaidan インターフェロンとリバビリンとの併用治療効果の検出方法および検出キット
KR20110074870A (ko) * 2008-09-24 2011-07-04 버텍스 파마슈티칼스 인코포레이티드 간염을 치료하기 위한 ｐｅｇ-인터페론, 리바비린 및 ｖｘ-950을 포함하는 치료 요법
WO2011132086A2 (en) 2010-04-21 2011-10-27 MeMed Diagnostics, Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
CN102178927A (zh) * 2011-03-01 2011-09-14 中国人民解放军军事医学科学院放射与辐射医学研究所 干扰素诱导跨膜蛋白3在制备抗乙型肝炎病毒感染药物中的用途
CN102323426A (zh) * 2011-08-08 2012-01-18 中国人民解放军军事医学科学院放射与辐射医学研究所 用于诊断或筛查丙型肝炎病毒感染的试剂
AU2013217935B2 (en) 2012-02-09 2018-05-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CA2948803A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
RU2730836C2 (ru) 2014-08-14 2020-08-26 Мемед Диагностикс Лтд. Вычислительный анализ биологических данных с применением многообразия и гиперплоскости
CN115054687A (zh) * 2014-08-22 2022-09-16 广州英恩迈生物医药科技有限公司 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
EP3230740B1 (en) 2014-12-11 2025-05-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
WO2017149547A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Analyzing rna for diagnosing infection type
US11274345B2 (en) 2016-06-07 2022-03-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of bacterial and viral infections
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
WO2018011795A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN108379584B (zh) * 2018-04-12 2020-08-11 上海交复生物医药科技有限公司 RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性
CN110448548B (zh) * 2018-05-08 2023-05-05 四川大学华西医院 Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途
KR102289533B1 (ko) * 2019-08-19 2021-08-17 주식회사 테라젠바이오 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램
CN111333710B (zh) * 2020-03-04 2021-12-03 暨南大学 C20orf24蛋白缺失突变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517960A (ja) * 2003-02-18 2006-08-03 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
US20050282179A1 (en) * 2003-12-05 2005-12-22 Applera Corporation Biomarkers for interferon-alpha response in hepatitis C virus infected patients
US7892735B2 (en) * 2004-12-30 2011-02-22 University Of Louisville Research Foundation, Inc. Genetic markers of schizophrenia spectrum disorders in the sulfotransferase 4a (sult4a) gene

Also Published As

Publication number Publication date
WO2007127801A2 (en) 2007-11-08
KR20090023360A (ko) 2009-03-04
CN101479389A (zh) 2009-07-08
NO20084954L (no) 2009-01-22
AU2007244824A1 (en) 2007-11-08
JP2009535036A (ja) 2009-10-01
EP2016195A4 (en) 2010-03-10
WO2007127801A3 (en) 2008-09-12
MX2008013796A (es) 2009-03-31
IL194920A0 (en) 2009-08-03
NZ573052A (en) 2012-03-30
EP2016195A2 (en) 2009-01-21
CA2650616A1 (en) 2007-11-08
US20100028874A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
Zhang et al. The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies
Barnaud et al. Thermal inactivation of infectious hepatitis E virus in experimentally contaminated food
Kash et al. Global suppression of the host antiviral response by Ebola-and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence
Oh et al. Acute hemorrhagic conjunctivitis caused by coxsackievirus A24 variant, South Korea, 2002
Liu et al. Transcriptome analysis of genes responding to NNV infection in Asian seabass epithelial cells
Moal et al. Chronic hepatitis E virus infection is specifically associated with an interferon-related transcriptional program
Duggal et al. Evidence for co-evolution of West Nile Virus and house sparrows in North America
JP2014519487A5 (enExample)
Porcella et al. Transcriptional profiling of human epithelial cells infected with plasmid-bearing and plasmid-deficient Chlamydia trachomatis
Zhao et al. Epidemiological and virological characterizations of the 2014 dengue outbreak in Guangzhou, China
Decaro et al. Evidence for circulation of bovine viral diarrhoea virus type 2c in ruminants in southern Italy
Pezzano et al. Hepatitis B virus in Buenos Aires, Argentina: genotypes, virological characteristics and clinical outcomes
Borges et al. Trapping the enemy: Vermamoeba vermiformis circumvents Faustovirus mariensis dissemination by enclosing viral progeny inside cysts
Yang et al. Immunopathogenesis of different emerging viral infections: evasion, fatal mechanism, and prevention
Teimouri et al. Single-nucleotide polymorphisms in host pattern-recognition receptors show association with antiviral responses against SARS-CoV-2, in-silico trial
Torres‐Puente et al. Genetic variability in hepatitis C virus and its role in antiviral treatment response
Dos Santos et al. Mutations associated with drug resistance and prevalence of vaccine escape mutations in patients with chronic hepatitis B infection
Álvarez-Torres et al. Molecular characterization and expression analyses of the Solea senegalensis interferon-stimulated gene 15 (isg15) following NNV infections
Dehghan-Manshadi et al. Relative expression of toll-like receptors 2 and 7 mRNA in peripheral blood of patients with hepatitis C
Singh et al. Coronavirus: A threat to global public health
Grimes et al. Differentially regulated gene expression associated with hepatitis C virus clearance
Hoshino et al. Phylogenetic and phylodynamic analyses of hepatitis C virus subtype 1a in Okinawa, Japan
WO2009021121A4 (en) Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
El Zibaoui et al. An update on infectious encephalitis: from epidemiology to management
Burt et al. Crimean-Congo Hemorrhagic Fever Virus: An Emerging and Re-emerging Pathogen of Public Health Concern

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130319